



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office. T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax 0091-11-26498341, 26494708, Phone: 0091-11-46181100, 46109900
Email: nandita.singh@jagsonpal.com
CIN No. L74899DL1978PLC009181

Date: March 31st, 2022

To,
The Department of Corporate Services-
Listing
BSE Ltd,
Phiroze Jeejeebhoy Towers,
Dalai Street
Mumbai-400 001

Scrip Code: 507789

To,
The Department of Corporate Services-
Listing
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kuria Complex,
Bandra (E)
Mumbai — 400 051
Symbol: JAGSNPHARM

Sub: Intimation of Closure of Trading Window

Dear Sir/ Madam

In terms of SEBI (Prohibition of Insider Trading) Regulations, 2015 (as amended) and Company's Code of Conduct to regulate, monitor and report trading by designated persons & immediate relatives of Designated Persons and pursuant to the clarification issued by NSE vide Ref No: NSE/CML/2019/11 dated 02.04.2019 on the provisions of Clause 4 of the Schedule B of SEBI (Prohibition of Insider Trading) Regulation, 2015 (as amended), the Trading Window for dealing in securities of Jagsonpal Pharmaceuticals Limited ("the Company") shall remain closed for Promoters, Designated Persons and their immediate relative(s) with effect from April 01, 2022 till the end of 48 hours after the declaration of financial results for the Quarter and year ended 31st March, 2022.

The same has been intimated to all the directors, officers and designated employees of the company.

The date of Board Meeting for declaration of the financial results of the Company for the Quarter and year ended 31st March, 2022 will be intimated in due course.

You are requested to take the above information on record.

For Jagsonpal Pharmaceuticals Limited


Nandita Singh
Company Secretary and Compliance Officer

